Deep immune cell profiling in blood and bone marrow of early stage monoclonal gammopathy: an iStopMM and ECRIN-M3 collaborative study.

COI Statement

Competing interests: SR, honoraria for scientific talks from Siemens Healthineers, Johnson & Johnson. ST, honoraria for scientific talks from Abbvie, Thermo Fisher. SYK, research funding from Amgen and Celgene; Independent Data Monitoring Committee for Jansen. Ethical approval: Written informed consent was given by each donor according to the Declaration of Helsinki. The study was approved by the National Bioethics Committee (NCT03327597) and the Icelandic Data Protection Agency; the Spanish Ministry of Health granted permission (Registration number: 2020/252) for the transfer of the biological samples.

References:

• Dhodapkar MV. The immune system in multiple myeloma and precursor states: lessons and implications for immunotherapy and interception. Am J Hematol. 2023;98:S4–12.
• McCachren SS, Dhodapkar KM, Dhodapkar MV. Co-evolution of immune response in multiple myeloma: implications for immune prevention. Front Immunol. 2021;12:1–13.
• García-Ortiz A, Rodríguez-García Y, Encinas J, Maroto-Martín E, Castellano E, Teixidó J, et al. The role of tumor microenvironment in multiple myeloma development and progression. Cancers. 2021;13:1–22.
• Rögnvaldsson S, Love TJ, Thorsteinsdottir S, Reed ER, Óskarsson JÞ, Pétursdóttir Í, et al. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer J. 2021;11:94.
• Schmidt-Hieber M, Pérez-Andrés M, Paiva B, Flores-Montero J, Perez JJ, Gutierrez NC, et al. CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features. Haematologica. 2011;96:328–32.